U.S. markets open in 4 hours 24 minutes
  • S&P Futures

    3,370.00
    +18.00 (+0.54%)
     
  • Dow Futures

    27,823.00
    +159.00 (+0.57%)
     
  • Nasdaq Futures

    11,480.00
    +72.75 (+0.64%)
     
  • Russell 2000 Futures

    1,512.70
    +8.30 (+0.55%)
     
  • Crude Oil

    39.84
    -0.38 (-0.94%)
     
  • Gold

    1,899.50
    +4.00 (+0.21%)
     
  • Silver

    23.67
    +0.18 (+0.77%)
     
  • EUR/USD

    1.1729
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    0.6770
    0.0000 (0.00%)
     
  • Vix

    25.99
    -0.28 (-1.07%)
     
  • GBP/USD

    1.2842
    -0.0079 (-0.61%)
     
  • USD/JPY

    105.5750
    +0.1450 (+0.14%)
     
  • BTC-USD

    10,893.98
    +97.94 (+0.91%)
     
  • CMC Crypto 200

    225.53
    +4.14 (+1.87%)
     
  • FTSE 100

    5,899.31
    +33.21 (+0.57%)
     
  • Nikkei 225

    23,184.93
    -0.19 (-0.00%)
     

Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat during the 2020 Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 3:30 p.m. EDT.

In order to participate in the audio webcast, interested parties can access the live webcast under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

ABOUT AURINIA

Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company is currently developing the investigational drug voclosporin for the treatment of lupus nephritis, other proteinuric kidney diseases and dry eye syndrome. Aurinia’s head office is in Victoria, British Columbia, its U.S. commercial hub in Rockville, Maryland, and focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200601005585/en/

Contacts

Investor & Corporate Contact:
Glenn Schulman, PharmD, MPH
SVP, Corporate Communications & IR
gschulman@auriniapharma.com